Sustained low hospitalization rates after four years of rotavirus mass vaccination in Austria

Vaccine. 2013 May 31;31(24):2686-91. doi: 10.1016/j.vaccine.2013.04.001. Epub 2013 Apr 15.

Abstract

This hospital based surveillance study evaluates the effects of the rotavirus mass vaccination program, which was initiated in Austria in August 2007. Since then, incidence rates of rotavirus hospitalizations in children <15 years of age have decreased by 70% and 64% in 2010 and 2011 compared to the pre-vaccination era (2001-2005). Incidence rates were highest in children <90 days of age, highlighting the importance of the early start of active rotavirus immunization. In children between 2 and 3.5 years in 2011, who were in the second and third year after vaccination in the universal mass vaccination program, incidence rates remained low suggesting sustained protection after vaccination up to three years. In the years 2010 and 2011, field effectiveness of the vaccines was between 79% and 96%, depending on the assumptions made for children without information on vaccination history. From genotyping an increase of the prevalence of G2P[4] in children with breakthrough infection (disease despite vaccination) can be suspected. The rate of severe adverse events was 1.3-1.5 per 10(-5) administered doses of rotavirus vaccines and no death, intussusception or Kawasaki disease was reported in 2010 and 2011 following rotavirus vaccination.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Austria / epidemiology
  • Child
  • Child, Preschool
  • Female
  • Genotype
  • Hospitalization / statistics & numerical data
  • Humans
  • Intussusception / epidemiology
  • Intussusception / prevention & control
  • Male
  • Mass Vaccination / statistics & numerical data*
  • Prevalence
  • Rotavirus / immunology*
  • Rotavirus Infections / epidemiology*
  • Rotavirus Infections / prevention & control
  • Rotavirus Vaccines / administration & dosage*
  • Rotavirus Vaccines / adverse effects
  • Rotavirus Vaccines / immunology

Substances

  • Rotavirus Vaccines